This video episode discusses various new therapies and strategies for treating patients with high-risk BCG-unresponsive NMIBC. It includes a review of nadofaragene firadenovec-vncg, its FDA approval, dosing schedule, and patient response rates. The conversation also explores the practical aspects of treatment, such as the balance between efficacy and treatment frequency, and the potential sequencing of therapies in clinical practice.
This video segment provides insights into various innovative trials and agents being explored for high-risk BCG-unresponsive NMIBC. The discussion covers a range of approaches including oncolytic immunotherapy, gene therapy, systemic IO agents, antibody-drug conjugates, and cytokine therapies. It emphasizes the need for personalized dosing regimens based on individual immune responses and highlights the significance of longer-term efficacy evaluations beyond initial three-month response rates.
"It's no surprise that there are many people interested in active surveillance and how we can be doing it better," says Kevin Shee, MD, PhD.
"This is just another way that we can exploit the body's own natural system to take care of cancer," says Daniel P. Petrylak, MD.
"What we found was that the primary outcome didn't change. Whether you had access to eADVICE or you didn't, most people still wanted to see the specialist at the end of their time, including people who were already dry," says Patrina H. Y. Caldwell, BMed, FRACP, PhD.
"If you suspect that you have a calcium oxalate monohydrate stone, we found that the most effective settings are 0.4 J and 40 Hz, and maybe as a backup setting, 0.2 J and 100 Hz," says Ojas Shah, MD.
"I think that, across industries, AI is going to provide a great benefit to our day-to-day practice," says Michael Karellas, MD.
"The reason we did this study was that in Australia, there are usually very long waiting times to be seen in the continence service," says Patrina H. Y. Caldwell, BMed, FRACP, PhD.
"There is a real importance for qualitative research and understanding the patient's experience and voice whether it's incontinence or any other condition," says Lindsay A. Hampson, MD, MAS.
"Probably the most common scenario that we get a lot of parental concerns about are the patients that only have bedwetting, and it just never went away," says Miriam Harel, MD.
Urologists and radiation oncologists discuss the multidisciplinary approach to treating patients with prostate cancer and how they address treatment complications.
A detailed overview of clinical trials and ongoing research in prostate cancer investigating rectal spacers.
"It's really gratifying to see how the field has changed over the last 10 years," says Daniel P. Petrylak, MD.
"PLUS was created to start laying down the foundation for implementing prevention science, and understanding things that helped maintain bladder health [and] things that are risk factors for progression into bladder disease," says Leslie Rickey, MD, MPH.
"There is a definite shortage, so not just increasing the diversity, but we have to increase the work force itself," says Sumit Saini, MD
"For the first 3 years that people join us, there's a whole program set up for them to help assimilate them into the culture, get them the resources that they need, make sure that they're meeting their benchmarks and goals," says Anne M. Suskind, MD, MS, FACS, FPMRS.
This episode provides an in-depth discussion on Cretostimogene Grenadenorepvec (CG), an investigational agent for high-risk BCG-unresponsive NMIBC, including the mechanism of action, its efficacy and safety data from clinical trial trials like CORE01 and BOND-003 (NCT04452591), and the rationale behind combining CG with anti-PD-1/PD-L1 antibodies. Experts also provide their insights on future directions in clinical development and application of CG in various NMIBC treatment scenarios, such as a monotherapy and in combination with IO, including its potential use in intermediate-risk disease.
This episode explores the potential of emerging therapies in providing effective treatment alternatives for challenging NMIBC cases. Current clinical trials and investigational treatments for high-risk, BCG-unresponsive NMIBC are highlighted, including the use of N-803, an IL-15 superagonist, in combination with BCG, and discusses TAR-200, an intravesical drug delivery system, which releases gemcitabine directly into the bladder over time.
“There are a lot of people using this technology now, but it is not mainstream by any means,” says Ojas Shah, MD.
"Ask about leakage and talk about options," says Lindsay A. Hampson, MD, MAS.
"I think as urologists that treat incontinence, both Dr. Shaw and I probably have the experience of talking to many men who actually never pursue surgical treatment for their incontinence, but they still want to understand what the options are," says Lindsay A. Hampson, MD, MAS.
"I find writing kind of relaxing. I like it like I like sitting down and reading for an hour," says Andrew L. Siegel, MD.
“These are key, because right now our sepsis rates following ureteroscopy are, quite frankly, unacceptable,” says Jordan L. Allen, MD.
"For me, the take-home message is that reduced or even no-narcotic discharge for patients after kidney surgery is feasible, and that it really should be our mindset of, can we reduce the amount of opioids we use?" says Craig G. Rogers, MD.
"I think the main [finding] that continues to strike me working with Dr Hampson on this type of work is how different individual incontinence is for the patient who is experiencing it," says Nathan M. Shaw, MD.
Prostate cancer specialists outline the pros and cons of the rectal spacer options for patients with prostate cancer and discuss factors that influence spacer choice.
The expert panel outlines visibility considerations with the 3 rectal spacer options when treating patients with prostate cancer with radiation therapy.
Neal Shore, MD, FACS, offers clinical insights on optimizing patient selection and treatment sequencing in BCG-unresponsive NMIBC.
This monthly series will begin in January 2024, and attendees can earn one category 1 CME credit per session.
"Nowadays, the complexity of potential management options have gotten increasingly difficult to express to patients," says Andrew L. Siegel, MD.
